Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.
Saved in:
| Title: | Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas. |
|---|---|
| Authors: | Celay J; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Recalde M; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Revuelta MV; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA., Larrayoz M; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Vicente C; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Lozano T; Program of Immunology and Immunotherapy, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona, Spain., Gil C; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Chapman JR; Department of Pathology and Laboratory Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Garcia-Lacarte M; Department of Biochemistry and Genetics, Universidad de Navarra, IDISNA, CIBERONC, Pamplona, Spain., Gonzalez C; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Ariceta B; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Rodriguez S; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Lasa M; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Garcia-Barchino MJ; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Fresquet V; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Jimenez M; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Sanz S; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Du MQ; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK., Roncador G; Monoclonal Antibodies Unit, Spanish National Cancer Research Center CNIO, Biotechnology Program, Madrid, Spain., Vega Z; Histopathology Unit, Spanish National Cancer Research Center CNIO, Biotechnology Program, Madrid, Spain., Sacco A; Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civil Di Brescia, Brescia, Italy., Roccaro A; Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civil Di Brescia, Brescia, Italy., Knittel G; Department of Hematology and Stem Cell Transplantation, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, Germany., Reinhardt HC; Department of Hematology and Stem Cell Transplantation, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, Germany., Piazza R; Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy., Herter S; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Goodhew R; Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK., Caron J; Centre de Recherche Des Cordeliers, INSERM, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France., Roos-Weil D; Centre de Recherche Des Cordeliers, INSERM, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France., Miguel JS; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Canales M; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Hodson DJ; Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK., Lossos IS; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Lasarte JJ; Program of Immunology and Immunotherapy, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona, Spain., Roa S; Department of Biochemistry and Genetics, Universidad de Navarra, IDISNA, CIBERONC, Pamplona, Spain., Prosper F; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Paiva B; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain., Cerchietti L; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA. lec2010@med.cornell.edu.; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, 1300 York Ave., Meyer Research Building C-640, New York, NY, 10065, USA. lec2010@med.cornell.edu., Martinez-Climent JA; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain. jamcliment@unav.es.; Division of Hemato-Oncology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Avda. Pio XII, 55; 31008, Pamplona, Spain. jamcliment@unav.es. |
| Source: | Molecular cancer [Mol Cancer] 2026 Apr 20. Date of Electronic Publication: 2026 Apr 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
